Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI

Miyazawa, Kenji; Fogelson, Aaron L.; Leiderman, Karin

doi:10.1016/j.bpj.2022.11.023

Cited by 8 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the formation of blood clots is monitored in order to prevent platelet aggregation from interfering with the coagulation process [50,51]. Coagulation can also be caused by an individual's inner stimulation reagent, including ellagic acid or phospholipid [52], an extrinsic inducer solution, such as tissue factor [53], or all of these can be triggered by clotting inhibitors, such as cytochalasin D in combination with an exterior activator [54]. Previous analyses [55,56] evaluated various point-of-care (POC) devices for test results but instead briefly described their scanning principles, although this systematic looked into other blood clotting checking methodologies.…”

Section: Discussionmentioning

confidence: 99%

New and more effective application assays for hemostatic disorder assessment: A systematic review

Alzahrani

2023

ELECTRON J GEN MED

View full text Add to dashboard Cite

Background: Hemostasis research lacked novel platform assays for hemostatic disorder diagnosis. The current review study’s goal is to compare various assays for evaluating the novel hemostatic techniques used in the diagnosis of coagulation disturbances and to highlight each method’s strongest and weakest points. Methods: The PRISMA guidelines and the recommendations for observational studies in epidemiology were both followed in the current systematic review. The PRISMA-compliant electronic databases (PubMed), a novel platform for evaluating hemostasis, were searched using the keywords. The electronic databases (PubMed), a cutting-edge platform to assess hemostasis, were searched using the keywords. Articles published between December 2016 and December 2021 were only included in searches; original articles were written in English. In order to assess hemostasis studies, we gathered bibliographies of abstracts that were published on the new and more effective application assays for assessments of hemostasis disorders. Results: Following the removal of duplicates, articles were determined by examining the titles and abstracts. Disagreements were resolved through consensus and the application of novel hemostatic analysis methods. Then independently reviewed the relevant studies of the recognized records (n=503), excluding duplicates (n=9) and irrelevant studies (n=249). The remaining 254 studies were read in their entirety, the data from the seven included studies had been extracted. Conclusions: When expressed as an anticoagulant for the in vivo assessment of on the complement system, nanotechnology-based study was more effective in some laboratory tests, and flow cytometer evaluation could be a promising platform approach for use in hemostasis management.

show abstract

Section: Discussionmentioning

confidence: 99%

New and more effective application assays for hemostatic disorder assessment: A systematic review

Alzahrani

2023

ELECTRON J GEN MED

View full text Add to dashboard Cite

show abstract

“…Moreover, a series of protease inhibitors such as serine protease inhibitors (SERPIN) [ 32 ], including AT, heparin cofactor II, protein-Z-dependent protease inhibitors (ZPI), protease nexin 1, and the C1 inhibitor exerts a negative control of coagulation and fibrinolysis. Other non-SERPIN anticoagulants, such as TFPI, the chief inhibitor of the TF-FVIIa complex, also play a role [ 33 ]. In addition, APC, together with protein S (PS), its main cofactor, are crucial physiological inhibitors of FVa and FVIIIa [ 34 ].…”

Section: Hemostasis and Its Regulationmentioning

confidence: 99%

The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency

Pablo-Moreno

Miguel-Batuecas

Sancha

et al. 2023

IJMS

View full text Add to dashboard Cite

Proteostasis, i.e., the homeostasis of proteins, responsible for ensuring protein turnover, is regulated by proteases, which also participate in the etiopathogenesis of multiple conditions. The magic of proteases is such that, in blood coagulation, one same molecule, such as coagulation factor V, for example, can perform both a procoagulant and an anticoagulant function as a result of the activity of proteases. However, this magic has an insidious side to it, as it may also prevent the completion of the clinical value chain of factor V deficiency. This value chain encompasses the discovery of knowledge, the transfer of this knowledge, and its translation to clinical practice. In the case of rare and ultra-rare diseases like factor V deficiency, this value chain has not been completed as the knowledge acquisition phase has dragged out over time, holding up the transfer of knowledge to clinical practice. The reason for this is related to the small number of patients afflicted with these conditions. As a result, new indications must be found to make the therapies cost-effective. In the case of factor V, significant research efforts have been directed at developing a recombinant factor V capable of resisting the action of the proteases capable of inactivating this factor. This is where bioethics and health equity considerations come into the equation.

show abstract

“…The reactions culminate in the generation of the enzyme thrombin on activated platelet surfaces, which is a strong platelet activation agonist, a key player in positive feedback, and converts fibrinogen into fibrin, which polymerizes and forms a stabilizing fibrin gel on the platelet plug. Platelets play a critical role in coagulation, as thrombin generation and inhibition is strongly regulated by their activated surfaces [ 1 – 4 ]. Thrombin generation is often used as a clinical indicator of healthy clotting, as without thrombin, a clot is typically leaky and unstable.…”

Section: Motivation and Significancementioning

confidence: 99%

clotFoam: An open-source framework to simulate blood clot formation under arterial flow

2023

View full text Add to dashboard Cite

Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI

Cited by 8 publications

References 59 publications

New and more effective application assays for hemostatic disorder assessment: A systematic review

New and more effective application assays for hemostatic disorder assessment: A systematic review

The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency

clotFoam: An open-source framework to simulate blood clot formation under arterial flow

Contact Info

Product

Resources

About